Search Results - "Gomes, Nathália Mota de Faria"
-
1
Differences between Risk Factors Associated with Tuberculosis Treatment Abandonment and Mortality
Published in Pulmonary Medicine (01-01-2015)“…Objectives. To identify the risk factors that were associated with abandonment of treatment and mortality in tuberculosis (TB) patients. Methods. This study…”
Get full text
Journal Article -
2
Risk factors for cancer in patients with primary biliary cholangitis and autoimmune hepatitis and primary biliary cholangitis overlap syndrome
Published in Annals of hepatology (01-07-2023)“…Primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) and PBC overlap syndrome (AIH/PBC) have been associated with a higher risk of hepatocellular…”
Get full text
Journal Article -
3
Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population
Published in Annals of hepatology (01-01-2022)“…Little is known about primary biliary cholangitis (PBC) in non-whites. The purpose of this study was to evaluate clinical features and outcomes of PBC in a…”
Get full text
Journal Article -
4
O-43 RISK FACTORS FOR CANCER DEVELOPMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
Published in Annals of hepatology (01-03-2023)“…Primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) and PBC overlap syndrome (AIH/PBC) have been associated with a higher risk of hepatocellular…”
Get full text
Journal Article -
5
Anti-mitochondrial Antibody-Negative Primary Biliary Cholangitis Is Part of the Same Spectrum of Classical Primary Biliary Cholangitis
Published in Digestive diseases and sciences (01-07-2022)“…Background Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease in which anti-mitochondrial antibodies (AMA) are the diagnostic hallmark…”
Get full text
Journal Article -
6
A new and simple score to predict adequate and deep response to ursodeoxycholic acid in patients with primary biliary cholangitis: the ALP-A score
Published in European journal of gastroenterology & hepatology (01-05-2024)“…Ursodeoxycholic acid (UDCA) is the standard treatment for primary biliary cholangitis (PBC), but a significant proportion of patients do not respond…”
Get full text
Journal Article -
7
Response to Ursodeoxycholic Acid May Be Assessed Earlier to Allow Second-Line Therapy in Patients with Unresponsive Primary Biliary Cholangitis
Published in Digestive diseases and sciences (01-02-2023)“…Background Response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) has been traditionally assessed 1 to 2 years after treatment…”
Get full text
Journal Article -
8
Alkaline phosphatase and liver fibrosis at diagnosis are associated with deep response to ursodeoxycholic acid in primary biliary cholangitis
Published in Clinics and research in hepatology and gastroenterology (01-10-2024)“…•Nomalization of alkaline phosphatase and bilirubin, defined as deep response, is a new treatment target for PBC.•Cirrhosis at diagnosis and elevated baseline…”
Get full text
Journal Article